Aurobindo Pharma share price touched a 52-week low of Rs 581, falling more than three percent, after the United States Food and Drug Administration (US FDA) issued six observations for the company's Hyderabad plant.
"The US FDA inspected Aurobindo Pharma's Unit VII, an oral manufacturing facility at Jedcherla, Hyderabad from May 2 to 10," the company said in its press release.
The company will respond to the US FDA within the stipulated timeline, it added.
At 09:20 hrs Aurobindo Pharma was quoting at Rs 591.65, down Rs 11.40 or 1.89 percent on the BSE.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
